Work

Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect

Year: 2025

Type: article

Abstract: Tirzepatide, an injectable agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, is used to treat type 2 diabetes mellitus and obesity. To our knowledge, there have been few reported cases of drug-induced liver injury (DILI) secondary to tirzepatide use. We report the experience of a 76-year-old woman who developed acute hepatitis following 8 weeks of tirzepatide use and a sixteen-pound weight loss. She was found to have elevated liver enzymes, and liver biopsy confirmed DILI. Though the mechanism underlying this DILI remains unknown, physicians should be aware of this rare side effect.

Source: ACG Case Reports Journal

DOI: 10.14309/crj.0000000000001661

Authors: Meagan Phox, John Thesing, W. Ransom Kilgore, Joel Alderson

Institutions: University of Kansas, Ascension Via Christi

Language: English

Topic: Drug-Induced Hepatotoxicity and Protection

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4409335245

FWCI: 6.871

Cites: 2

Cited by: 8

Related to: 10